Anti-interleukin-6 (tocilizumab) therapy in Takayasu's arteritis: real-life experience
| Autor: | Omer Karadag, Sedat Kiraz, Alper Sari, Ali Akdogan, Levent Kilic, Abdulsamet Erden, Berkan Armagan, Gözde Kübra Yardımcı, Esra Firat, Şule Apraş Bilgen, Ihsan Ertenli, Umut Kalyoncu |
|---|---|
| Přispěvatelé: | İç Hastalıkları |
| Rok vydání: | 2020 |
| Předmět: |
musculoskeletal diseases
medicine.medical_specialty Visual analogue scale Takayasu's arteritis 030204 cardiovascular system & hematology Gastroenterology tocilizumab 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Tocilizumab Refractory Internal medicine Medicine Arteritis skin and connective tissue diseases Interleukin 6 Tıp uygulaması 0303 health sciences biology medicine.diagnostic_test 030306 microbiology business.industry Takayasu’s arteritis General Medicine medicine.disease chemistry Erythrocyte sedimentation rate biology.protein Anti-interleukin-6 business Glucocorticoid medicine.drug |
| Zdroj: | TURKISH JOURNAL OF MEDICAL SCIENCES. |
| ISSN: | 1303-6165 |
| Popis: | Background/aim: Tumour necrosis factor inhibitors and anti-interleukin-6 (anti-IL-6) therapies are increasingly being used in Takayasu’s arteritis (TA) patients who are unresponsive to corticosteroids ± conventional immunosuppressive agents. The aim of this study is to assess the efficacy and safety of anti-IL-6 (tocilizumab) therapy in refractory TA patients in real life. Materials and methods: Fifteen TA patients (86.7% were female) who received at least 3 cycles of tocilizumab therapy were retrospectively assessed by clinical, laboratory, and radiological evaluations before and after tocilizumab therapy. Results: The median (min–max) age of the patients at evaluation was 35 (20–58) years and the median disease duration from diagnosis was 24 (12–168) months. The median (min.–max.) duration of follow-up after tocilizumab was 15 (3–42) months. There was a significant decrease in erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and patient global visual analogue scale (VAS) scores of patients after tocilizumab therapy. The median (min.–max.) ESR was 26 (5–119) vs. 3 (2–49) mm/h, P = 0.02; CRP was 39.8 (2.4–149.0) vs. 7.9 (0–92.9) mg/L, P = 0.017; and patient global VAS was 50 (0–90) vs. 30 (0–60), P = 0.027, respectively. In 8 patients, ESR and CRP levels were in the normal range in the last control. Imaging modality results after tocilizumab were available for 9 patients; 8 patients were radiologically stable and regression was seen in 1 patient. Comparable imaging modality results before and after tocilizumab were available for 5 patients; 4 patients were radiologically stable and regression was seen in 1 patient. Radiological findings were consistent with laboratory responses. Glucocorticoid dosages decreased from a mean dosage of 16.2 (9.1) mg/day at baseline to 7.1 (3.8) mg/day (P = 0.001) at the last follow-up visit. There was no increase in the steroid dosage in any of the patients. All patients tolerated tocilizumab well. Conclusion: Based on retrospective real life data, anti-IL-6 (tocilizumab) appears to be an effective and tolerable treatment option in refractory TA patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|